40.66
-0.95 (-2.27%)
| Penutupan Terdahulu | 41.60 |
| Jumlah Dagangan | 10,032,547 |
| Harga / Pendapatan (P/E Ke hadapan) | 12.49 |
| Harga / Jualan (P/S) | 3.56 |
| Harga / Buku (P/B) | 5.56 |
| Julat 52 Minggu | |
| Hasil Dividen (DY TTM) | 4.16% |
| Margin Keuntungan | 34.51% |
| Margin Operasi (TTM) | 49.68% |
| EPS Cair (TTM) | 3.67 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 14.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 85.70% |
| Nisbah Semasa (MRQ) | 0.740 |
| Aliran Tunai Operasi (OCF TTM) | 131.24 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 77.73 B |
| Pulangan Atas Aset (ROA TTM) | 23.29% |
| Pulangan Atas Ekuiti (ROE TTM) | 88.12% |
Sentimen Berita
-
Novo Nordisk (CPSE:NOVO B) Scores Phase 3 Win And EU Approval Across New Therapies
2 hari lalu, 7:11AM
-
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
2 hari lalu, 10:20AM
-
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
2 hari lalu, 9:00AM
-
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
semalam, 5:45AM
-
Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival
2 hari lalu, 10:06AM
-
CVS Sees a Possible Break-Even Point for GLP-1s
2 hari lalu, 9:11AM
AISkor Stockmoo
| Nilai 30% | 2.9 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Harga rendah berbanding pertumbuhan perolehannya. info | |
| Harga menyiratkan pertumbuhan perolehan -4.4% setahun; perniagaan boleh membiayai kira-kira 15.0% setahun. info | |
| Lebih murah daripada penilaian biasanya. Dikira separuh kerana pulangannya menurun. info | |
| Keuntungan kukuh. Kecairan jangka pendek nipis. Aliran tunai positif. info | |
| Pulangan jauh melebihi kos modalnya. Pulangan atas modal menurun. info | |
| Masa 30% | -2.4 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Harga dan purata bergeraknya tersusun dalam aliran menurun. Purata bergerak utamanya mendatar. Hampir dengan purata bergerak yang menurun. Di bawah purata bergerak jangka panjang, jadi tidak dinilai positif. info | |
| Corak Lilin info | NA |
| Di bawah garis aliran jangka sederhana. info | |
| Sentimen 20% | 0.2 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini bercampur atau neutral. info | |
| Wang Pintar 20% | -0.2 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih -0.12% daripada saham dalam pemfailan 13F terkini: 524 pemegang menambah, 768 mengurang (suku berakhir 30 Sep 2026). info | |
| Keadaan pasaran dan sektor neutral. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor mengatasi prestasi pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek meningkat. info | |
| Harga hampir dengan paras sokongan. info | |
| Skor Akhir | 0.13 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - General (US) | Bercampur | Menaik |
| Drug Manufacturers - General (Global) | Bercampur | Menaik | |
| Stok | Novo Nordisk A/S | Bercampur | Menurun |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| NVO | - | 4.16% | - | 5.56 |
| JNJ | - | 1.92% | - | 8.44 |
| PFE | - | 6.00% | - | 1.85 |
| ABBV | - | 3.18% | - | - |
| GSK | - | 3.66% | - | 4.08 |
| BMY | - | 4.36% | - | 5.54 |
|
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - General |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.01% |
| % Dimiliki oleh Institusi | 9.85% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Everett Harris & Co /Ca/ | 30 Sep 2026 | 6,468,494 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 9.98%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 524 | 62,257,772 |
| Berkurang | 768 | 54,817,083 |
| Baharu | 112 | 9,276,616 |
| Dijual habis | 223 | 20,728,045 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
Novo Nordisk, the maker of Wegovy® (semaglutide) injection and tablets, today announced a reimagined consumer experience to help people get started and stay supported on Wegovy®. Novocare® brings together treatment and coverage information, fast and free home delivery and a new app to help track… |
| 17 Nov 2026 | Yahoo Finance |
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump. |
| 16 Nov 2026 | Yahoo Finance |
Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®
Today, Novo Nordisk presented new research at ObesityWeek® 2026 exploring biomarkers related to bone health across multiple investigational amylin-based medicines in its weight loss pipeline.¹ The research builds on Novo's growing understanding of how molecules that activate both the amylin and… |
| 16 Nov 2026 | Yahoo Finance |
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
Novo secures EC approval for Frehemgo while CagriSema delivers up to 21% weight loss, adding momentum to its turnaround efforts amid intensifying obesity drug competition. |
| 16 Nov 2026 | Yahoo Finance |
Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival
Novo Nordisk has the blockbuster weight-loss drugs, but Amgen could become a serious contender with its next-generation obesity treatment. |
| 16 Nov 2026 | Yahoo Finance |
CVS Sees a Possible Break-Even Point for GLP-1s
Drugmakers could gain patients while earning less per prescription. |
| 16 Nov 2026 | Yahoo Finance |
CVS white paper aims to pressure drugmakers to lower GLP-1 prices
GLP-1s would save employers money in the long term if priced at $350 a month or less, the company found. “I would love to see this pressure [drugmakers] to bring down prices to something rational,” CMO Amy Compton-Phillips said. |
| 16 Nov 2026 | CNBC |
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12… |
| 16 Nov 2026 | Yahoo Finance |
Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035
Lilly's Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo's Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: Precedence Research Company Intelligence on Leaders, Pipelines, Investments and DealsOttawa, Nov. 16, 2026 (GLOBE NEWSWIRE) -- The global anti-obesity drugs… |
| 16 Nov 2026 | Yahoo Finance |
Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
Today, Novo Nordisk shared primary results from the phase 3 STEP Young trial evaluating the safety and efficacy of investigational once-weekly semaglutide injection, with a maximum dose of 1.7 mg or 2.4 mg based on baseline body weight, in combination with a reduced-calorie diet and increased… |
| 16 Nov 2026 | Yahoo Finance |
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 16 November 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated… |
| 16 Nov 2026 | Yahoo Finance |
Novo Nordisk (CPSE:NOVO B) Scores Phase 3 Win And EU Approval Across New Therapies
Novo Nordisk (CPSE:NOVO B) reported positive phase 3 results for its investigational obesity therapy CagriSema, supporting a future filing plan. The company received European Union approval for haemophilia A treatment FREHEMGO, with a launch planned in initial EU markets in 2026. Regulatory… |
| 16 Nov 2026 | Yahoo Finance |
Novo Nordisk Stock in Focus as New Obesity Drug Shows Promise
Nearly 68% of Patients Lost Weight Quickly on Novo's CagriSema… |
| 16 Nov 2026 | Yahoo Finance |
Novo Nordisk Shares Gain 2.4% Following Additional CagriSema Weight-Loss Trial Analyses
Novo Nordisk (NYSE:NVO) shares rose 2. 4% after the Danish pharmaceutical company presented additional findings from its REDEFINE 1 clinical trial, showing that participants who responded early to its experimental obesity treatment CagriSema achieved average weight loss of 25… |
| 16 Nov 2026 | Yahoo Finance |
Novo Nordisk Stock Rises on Obesity Drug Breakthrough
Novo Nordisk Stock Gets a Boost From Obesity Drug Results and New European Approval… |
| 15 Nov 2026 | Yahoo Finance |
Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
Hint: It’s not a bad investment idea. |
| 14 Nov 2026 | Yahoo Finance |
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors. |
| 14 Nov 2026 | Yahoo Finance |
Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026
Today, Novo Nordisk presented real-world findings from the SIGNAL and OCTANE studies at ObesityWeek® 2026, looking at how food noise scores changed for adults with overweight or obesity taking Wegovy® injection or Wegovy® pill.1,2 Both retrospective cohort analyses used de-identified patient data… |
| 14 Nov 2026 | Yahoo Finance |
Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology
Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. REDEFINE 9 is the first phase 3… |
| 13 Nov 2026 | Yahoo Finance |
FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
European Commission (EC) grants marketing authorisation for FREHEMGO® (denecimig) for haemophilia A (congenital FVIII deficiency), with or without inhibitors, in adults and children.FREHEMGO® is the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks and once-weekly prophylaxis in a… |
| 13 Nov 2026 | Yahoo Finance |
Novo Nordisk Submits Sickle Cell Disease Treatment Etavopivat for US and European Regulatory Approval
Novo Nordisk (NYSE:NVO) has submitted regulatory applications in the United States and Europe seeking approval for etavopivat, an investigational oral treatment for sickle cell disease in patients aged 12 years and older. The pharmaceutical company filed a New Drug Application (NDA) with the US… |
| 13 Nov 2026 | Yahoo Finance |
Novo Nordisk Seeks FDA, EMA Approval For Sickle Cell Disease Treatment – Here Are The Key Takeaways
Novo Nordisk said etavopivat could offer a new disease-modifying treatment option for people living with sickle cell disease if approved. |
| 13 Nov 2026 | Yahoo Finance |
Novo Nordisk (CPSE:NOVO B) Taps DJ Khaled As Oral Weight Loss Race Heats Up
Novo Nordisk (CPSE:NOVO B) has partnered with DJ Khaled to promote his Wegovy weight loss journey to a wider US audience. Eli Lilly has received the first Chinese regulatory approval for an oral GLP-1 weight loss pill, ahead of Novo Nordisk's own oral product. Novo Nordisk's obesity portfolio now… |
| 13 Nov 2026 | Yahoo Finance |
Eli Lilly Stocks Rise as China Approves Orforglipron Weight-Loss Pill
Lilly's oral obesity drug wins Chinese approval, setting up a fight with Novo Nordisk, Pfizer and Innovent in a vast market. |
| 13 Nov 2026 | Yahoo Finance |
Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval
Novo Nordisk today announced the submissions of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etavopivat, an investigational, once-daily, orally available, selective activator of… |
| 12 Nov 2026 | Yahoo Finance |
Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval
Lilly has become the first to get the regulatory nod for an oral weight loss medication in China, as competition in the cardiometabolic market heats up. |
| 12 Nov 2026 | Yahoo Finance |
Eli Lilly secures first approval for weight-loss pill in China
Eli Lilly and Co (NYSE:LLY), the American pharmaceutical group, has become the first drugmaker to secure Chinese approval for an oral glucagon-like peptide-1 (GLP-1) weight-loss treatment. The decision gives it an early lead over Novo Nordisk (NYSE:NVO) in the world’s second-largest… |
| 12 Nov 2026 | Yahoo Finance |
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
Novo Nordisk today announced a partnership with DJ Khaled for Wegovy® (semaglutide). The partnership is personal for Khaled, who has been taking Wegovy® for weight management since late 2025. Khaled will share his experience, covering topics such as weight loss and fatherhood, his real-life diet… |
| 02 Oct 2026 | CNBC | Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s |
| 30 Sep 2026 | CNBC | People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study |
| 25 Sep 2026 | CNBC | Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s |
| 21 Sep 2026 | CNBC | Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs |
| 21 Sep 2026 | CNBC | Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production |
| 14 Sep 2026 | CNBC | Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy |
| 31 Aug 2026 | CNBC | Trump strikes new drug pricing deals with nine midsized drugmakers |
| Papar semua | ||
| Hasil Dividen (DY TTM) | 4.16% |
| Purata Hasil Dividen 5T | 2.17% |
| Nisbah Pembayaran | 47.09% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 31 Mar 2025 | 05 Feb 2025 | 08 Apr 2025 | 1.099206 Tunai |
| 16 Aug 2024 | 06 Aug 2024 | 26 Aug 2024 | 0.5126402 Tunai |
| 22 Mar 2024 | 31 Jan 2024 | 02 Apr 2024 | 0.92985 Tunai |
| 18 Aug 2023 | 10 Aug 2023 | 29 Aug 2023 | 0.8835613 Tunai |
| 24 Mar 2023 | 02 Feb 2023 | 04 Apr 2023 | 1.1887415 Tunai |
| 12 Aug 2022 | 04 Aug 2022 | 23 Aug 2022 | 0.5835507 Tunai |
| 25 Mar 2022 | 02 Mar 2022 | 05 Apr 2022 | 1.022423 Tunai |
| 16 Aug 2021 | - | 25 Aug 2021 | 0.5502889 Tunai |
| 26 Mar 2021 | - | 07 Apr 2021 | 0.922122 Tunai |
| 14 Aug 2020 | 06 Aug 2020 | 25 Aug 2020 | 0.5177774 Tunai |
| 27 Mar 2020 | 06 Feb 2020 | 07 Apr 2020 | 0.7826048 Tunai |
| 16 Aug 2019 | 10 Aug 2019 | 27 Aug 2019 | 0.449438 Tunai |
| 22 Mar 2019 | 05 Feb 2019 | 02 Apr 2019 | 0.777006 Tunai |
| 17 Aug 2018 | 09 Aug 2018 | 28 Aug 2018 | 0.462327 Tunai |
| 23 Mar 2018 | 24 Mar 2018 | 03 Apr 2018 | 0.805982 Tunai |
| 17 Aug 2017 | - | 29 Aug 2017 | 0.33589 Tunai |
| 23 Mar 2017 | - | 04 Apr 2017 | 0.479369 Tunai |
| 11 Aug 2016 | - | 23 Aug 2016 | 0.331026 Tunai |
| 18 Mar 2016 | - | 30 Mar 2016 | 0.69943 Tunai |
| 19 Mar 2015 | - | 31 Mar 2015 | 0.532885 Tunai |
| 21 Mar 2014 | - | 02 Apr 2014 | 0.606122 Tunai |
| 21 Mar 2013 | - | 02 Apr 2013 | 2.264307 Tunai |
| 22 Mar 2012 | - | 03 Apr 2012 | 1.831902 Tunai |
| 24 Mar 2011 | - | 05 Apr 2011 | 1.357901 Tunai |
| 25 Mar 2010 | - | 07 Apr 2010 | 0.978615 Tunai |
| 19 Mar 2009 | - | 31 Mar 2009 | 0.781532 Tunai |
| 13 Mar 2008 | - | 25 Mar 2008 | 0.678462 Tunai |
| 08 Mar 2007 | - | 20 Mar 2007 | 0.891779 Tunai |
| 09 Mar 2006 | - | 21 Mar 2006 | 0.691753 Tunai |
| 10 Mar 2005 | - | 22 Mar 2005 | 0.61725 Tunai |
| 17 Mar 2004 | - | 29 Mar 2004 | 0.52096 Tunai |
| 26 Mar 2003 | - | 07 Apr 2003 | 0.37647 Tunai |
| 13 Mar 2002 | - | 25 Mar 2002 | 0.2848 Tunai |
| 21 Mar 2001 | - | 02 Apr 2001 | 0.5681 Tunai |
| 24 Mar 2000 | - | 06 Apr 2000 | 0.4672 Tunai |
| 25 Mar 1999 | - | 06 Apr 1999 | 0.4182 Tunai |
| 27 Mar 1998 | - | 08 Apr 1998 | 0.3051 Tunai |
| 25 Apr 1997 | - | 07 May 1997 | 0.239 Tunai |
| 01 May 1996 | - | 14 May 1996 | 0.1806 Tunai |
| Papar semua | |||
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2025 | 1.10 | 1 | 2.16 |
| 2024 | 1.44 | 2 | 1.68 |
| 2023 | 2.07 | 2 | 2.00 |
| 2022 | 1.61 | 2 | 2.37 |
| 2021 | 1.47 | 2 | 2.63 |
| 2020 | 1.30 | 2 | 3.72 |
| 2019 | 1.23 | 2 | 4.24 |
| 2018 | 1.27 | 2 | 5.51 |
| 2017 | 0.815 | 2 | 3.04 |
| 2016 | 1.03 | 2 | 5.75 |
| 2015 | 0.533 | 1 | 1.84 |
| 2014 | 0.606 | 1 | 2.86 |
| 2013 | 2.26 | 1 | 12.26 |
| 2012 | 1.83 | 1 | 11.22 |
| 2011 | 1.36 | 1 | 11.78 |
| 2010 | 0.979 | 1 | 8.69 |
| 2009 | 0.782 | 1 | 12.24 |
| 2008 | 0.678 | 1 | 13.20 |
| 2007 | 0.892 | 1 | 13.75 |
| 2006 | 0.692 | 1 | 16.54 |
| 2005 | 0.617 | 1 | 21.94 |
| 2004 | 0.521 | 1 | 19.20 |
| 2003 | 0.376 | 1 | 18.38 |
| 2002 | 0.285 | 1 | 19.71 |
| 2001 | 0.568 | 1 | 28.33 |
| 2000 | 0.467 | 1 | 26.40 |
| 1999 | 0.418 | 1 | 32.36 |
| 1998 | 0.305 | 1 | 22.94 |
| 1997 | 0.239 | 1 | 16.57 |
| 1996 | 0.181 | 1 | 19.32 |
| Papar semua | |||
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |